MATX vs MYRG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MATX exhibits exceptional financial health with a Piotroski F-Score of 8/9, indicating strong operational efficiency and balance sheet stability. While the current price ($173.35) sits slightly above the Graham Number ($167.93), it remains significantly undervalued relative to its growth-based intrinsic value of $407.4. Despite a recent decline in revenue growth (-4.30%), the company has maintained strong earnings growth (21.20%) and a consistent track record of beating EPS estimates. The primary headwinds are bearish insider sentiment and a critical regulatory dependency on the Jones Act.
MYRG exhibits strong operational health with a Piotroski F-Score of 7/9 and a very conservative debt-to-equity ratio of 0.16. However, the stock is currently trading at a significant premium, with a current price of $330.97 far exceeding both the Graham Number ($84.84) and the growth-based Intrinsic Value ($221.84). While explosive earnings growth (137.10% YoY) justifies some premium, the high PEG ratio (3.41) and bearish technical trend suggest the stock is overextended. The disconnect between fundamental strength and valuation creates a neutral outlook for new entries.
Compare Another Pair
Related Comparisons
MATX vs MYRG: Head-to-Head Comparison
This page compares Matson, Inc. (MATX) and MYR Group Inc. (MYRG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.